The Food and Drug Administration recently updated its  to note that the monoclonal antibody is not expected to neutralize omicron subvariants BQ.1 and BQ.1.1. While bebtelovimab remains authorized in all U.S. regions until further notice, prescribers should monitor the Centers for Disease Control and Prevention’s  and refer to the provider fact sheet for details regarding resistance against SARS-CoV-2 variants in their area, . 

In other news, FDA yesterday  that naloxone may not be able to reverse the effects of xylazine in fentanyl, heroin and other illicit drug overdoses. FDA is aware of increasing reports of serious side effects from individuals exposed to fentanyl, heroin and other illicit drugs contaminated with xylazine, a sedative and pain reliever that FDA has approved for use in animals.

Related News Articles

Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…
Headline
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,…
Headline
In this conversation, Matthew Hoag, director of integrated behavioral health at Denver Health, shares how the organization is innovating through integration to…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…